The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy
AbstractDNA-based vaccine strategy is increasingly realized as a viable cancer treatment approach. Strategies to enhance immunogenicity utilizing tumor associated antigens have been investigated in several pre-clinical and clinical studies. The promising outcomes of these studies have suggested that DNA-based vaccines induce potent T-cell effector responses and at the same time cause only minimal side-effects to cancer patients. However, the immune evasive tumor microenvironment is still an important hindrance to a long-term vaccine success. Several options are currently under various stages of study to overcome immune inhibitory effect in tumor microenvironment. Some of these approaches include, but are not limited to, identification of neoantigens, mutanome studies, designing fusion plasmids, vaccine adjuvant modifications, and co-treatment with immune-checkpoint inhibitors. In this review, we follow a Porter’s analysis analogy, otherwise commonly used in business models, to analyze various immune-forces that determine the potential success and sustainable positive outcomes following DNA vaccination using non-viral tumor associated antigens in treatment against cancer. View Full-Text
Share & Cite This Article
Amara, S.; Tiriveedhi, V. The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int. J. Mol. Sci. 2017, 18, 650.
Amara S, Tiriveedhi V. The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. International Journal of Molecular Sciences. 2017; 18(3):650.Chicago/Turabian Style
Amara, Suneetha; Tiriveedhi, Venkataswarup. 2017. "The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy." Int. J. Mol. Sci. 18, no. 3: 650.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.